Matches in SemOpenAlex for { <https://semopenalex.org/work/W2682386311> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2682386311 abstract "Aims: If the persistence of ITC after adjuvant therapy is associated with risk for recurrence, it would be an indication to consider secondary adjuvant treatment. Cell-cycle independent agents might be effective in the elimination of dormant cells. Methods: We analyzed BM aspirates from 228 pts during recurrence-free follow-up at a median interval of 21.3mon after primary diagnosis. ITC were detected by monoclonal antibody A45-B/B3 against cytokeratin. Pts were followed for a median of 49.8mon. In a pilot study on 14 pts with evidence of persisting ITC, zoledronate was applied (4mg q4wx6mon, loading dose 8mg). Pts were to have completed surgery (R0) and adjuvant chemotherapy for at least 6mon. In a matched pair analysis, these pts were compared to 14 pts with persisting ITC in the BM, who received no further therapy. The BM was re-examined after a median of 8mon in the treatment group and 9mon in the control group. Results: Persistent ITC in BM were detected in 12.7% of pts. Positive BM status was more frequent (15.7%) within the first 21mon after primary diagnosis than after a follow-up>21mon (9.7%). Recurrence-free survival was 149mon in pts with negative and 86mon in pts with positive BM status (P=.0003). Pts who were without evidence of persistent ITCs had a significantly longer overall survival (162.1 vs. 98.7mon; P=.0008). In multivariate analysis ITC was an independent predictor for disease-free (RR 4.57; P<.0001) and overall survival (RR 5.57; P=.002). While ITC were detected in all 28 pts of the therapeutic intervention study at initial BM aspiration, no pt showed ITC in the BM after 6mon of zoledronate. ITC were detected in 4 pts (29%) of the control group (P=.03). Conclusions: Evidence of persistent ITCs in BM from pts with breast carcinoma indicated an increased risk for subsequent recurrence. Secondary adjuvant treatment intervention with zoledronate might have a potential antineoplastic effect on persisting ITC in dormant state." @default.
- W2682386311 created "2017-06-30" @default.
- W2682386311 creator A5008649645 @default.
- W2682386311 creator A5010293363 @default.
- W2682386311 creator A5010695689 @default.
- W2682386311 creator A5026216861 @default.
- W2682386311 creator A5034157963 @default.
- W2682386311 creator A5044467977 @default.
- W2682386311 creator A5058112938 @default.
- W2682386311 creator A5082681201 @default.
- W2682386311 creator A5087227508 @default.
- W2682386311 date "2005-10-18" @default.
- W2682386311 modified "2023-10-17" @default.
- W2682386311 title "Prognostic Significance of Isolated Tumor Cells (ITC) in the Bone Marrow (BM) of Breast Cancer Patients During Recurrence-free Follow-up and Therapeutic Intervention with Zoledronate" @default.
- W2682386311 doi "https://doi.org/10.1055/s-2005-921013" @default.
- W2682386311 hasPublicationYear "2005" @default.
- W2682386311 type Work @default.
- W2682386311 sameAs 2682386311 @default.
- W2682386311 citedByCount "0" @default.
- W2682386311 crossrefType "journal-article" @default.
- W2682386311 hasAuthorship W2682386311A5008649645 @default.
- W2682386311 hasAuthorship W2682386311A5010293363 @default.
- W2682386311 hasAuthorship W2682386311A5010695689 @default.
- W2682386311 hasAuthorship W2682386311A5026216861 @default.
- W2682386311 hasAuthorship W2682386311A5034157963 @default.
- W2682386311 hasAuthorship W2682386311A5044467977 @default.
- W2682386311 hasAuthorship W2682386311A5058112938 @default.
- W2682386311 hasAuthorship W2682386311A5082681201 @default.
- W2682386311 hasAuthorship W2682386311A5087227508 @default.
- W2682386311 hasConcept C121608353 @default.
- W2682386311 hasConcept C126322002 @default.
- W2682386311 hasConcept C141071460 @default.
- W2682386311 hasConcept C143998085 @default.
- W2682386311 hasConcept C2776694085 @default.
- W2682386311 hasConcept C2777863537 @default.
- W2682386311 hasConcept C2777982462 @default.
- W2682386311 hasConcept C2780007613 @default.
- W2682386311 hasConcept C50382708 @default.
- W2682386311 hasConcept C530470458 @default.
- W2682386311 hasConcept C71924100 @default.
- W2682386311 hasConcept C90924648 @default.
- W2682386311 hasConceptScore W2682386311C121608353 @default.
- W2682386311 hasConceptScore W2682386311C126322002 @default.
- W2682386311 hasConceptScore W2682386311C141071460 @default.
- W2682386311 hasConceptScore W2682386311C143998085 @default.
- W2682386311 hasConceptScore W2682386311C2776694085 @default.
- W2682386311 hasConceptScore W2682386311C2777863537 @default.
- W2682386311 hasConceptScore W2682386311C2777982462 @default.
- W2682386311 hasConceptScore W2682386311C2780007613 @default.
- W2682386311 hasConceptScore W2682386311C50382708 @default.
- W2682386311 hasConceptScore W2682386311C530470458 @default.
- W2682386311 hasConceptScore W2682386311C71924100 @default.
- W2682386311 hasConceptScore W2682386311C90924648 @default.
- W2682386311 hasIssue "04" @default.
- W2682386311 hasLocation W26823863111 @default.
- W2682386311 hasOpenAccess W2682386311 @default.
- W2682386311 hasPrimaryLocation W26823863111 @default.
- W2682386311 hasRelatedWork W1603749692 @default.
- W2682386311 hasRelatedWork W1735392790 @default.
- W2682386311 hasRelatedWork W2163676795 @default.
- W2682386311 hasRelatedWork W2379009234 @default.
- W2682386311 hasRelatedWork W2387957804 @default.
- W2682386311 hasRelatedWork W2388730008 @default.
- W2682386311 hasRelatedWork W2769256842 @default.
- W2682386311 hasRelatedWork W2982480961 @default.
- W2682386311 hasRelatedWork W3037464086 @default.
- W2682386311 hasRelatedWork W3140477201 @default.
- W2682386311 hasVolume "127" @default.
- W2682386311 isParatext "false" @default.
- W2682386311 isRetracted "false" @default.
- W2682386311 magId "2682386311" @default.
- W2682386311 workType "article" @default.